Urology & Uro-oncology

science-innovation-2

Urology & Uro-oncology

We are developing medicines and researching early stage treatments as part of our sustained commitment to specialty innovation.

Urology & Uro-oncology

Ferring is committed to the development of medicines to treat urological disorders such as diabetes insipidus, enuresis and nocturia. Ferring’s lead product in this area is MINIRIN® (desmopressin) which effectively treats enuresis in children and nocturia in adults. A vasopressin receptor agonist designed to bring additional treatment benefits in this therapy area is in early stage development.

For the treatment of patients with advanced prostate cancer, Ferring has launched a 1-month dosing regimen of FIRMAGON® (degarelix), a gonadotropin-releasing hormone (GnRH) receptor antagonist, in the US, Europe and through a partner in Japan. We are conducting clinical studies to further demonstrate the benefits of therapy using a (GnRH) receptor antagonist in the treatment of advanced prostate cancer.

Discover more about bladder cancer,

prostate cancer, bedwetting and nocturia

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.

OK

Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.

OK

Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals

OK

Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.

OK

Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.

OK

Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.

OK